pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-499a |
Genomic Coordinates | chr20: 34990376 - 34990497 |
Description | Homo sapiens miR-499a stem-loop |
Comment | The mature sequence shown here represents the most commonly cloned form from large-scale cloning studies . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-499a-3p | ||||||||||||||||||||||||||||||
Sequence | 70| AACAUCACAGCAAGUCUGUGCU |91 | ||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ABLIM1 | ||||||||||||||||||||
Synonyms | ABLIM, LIMAB1, LIMATIN, abLIM-1 | ||||||||||||||||||||
Description | actin binding LIM protein 1 | ||||||||||||||||||||
Transcript | NM_001003407 | ||||||||||||||||||||
Other Transcripts | NM_002313 , NM_006720 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ABLIM1 | |||||||||||||||||||||
3'UTR of ABLIM1 (miRNA target sites are highlighted) |
>ABLIM1|NM_001003407|3'UTR 1 GTCCCACTCGTGAATGGCAATTAGAGAAAGGACTGACAGTGGCGGTGCCCCATAGGATGTCATATTGAGGCCCAAACTTG 81 ATTGGAGAATTTGCAAACTACCGTCGCTCAGCAACACCAAAAAGAGAAAGTCTGGTTAAAACACCATGAGTCAAATGTCG 161 GGCCAGCCAACAGTAACACTTGCCAAGAAGCATGGCGTAGAAATTTCTATGTTCCGAAACACAGAGTAGTGTCCACATGT 241 GAGCTTTTCACATTACCTTATGTATACAACAGGAGCTGCGTTGTTTTCTTCTTTTTCTTTTCCTTTATCTGTTGTCCAAC 321 AACAGTGCTGACTGTCCGGATAAGAGCTGGCAAGTGCCCTTAGGATGCCGCATGGGAAAAATCGGTTATCATAATTTCAA 401 AGTATAAATATATTTATTAAGTAGCGCTGCGGCTAAGAAGGAAGAGTGAGGGGTCTGTCCATGGGGTGGCAGTGATTTCA 481 CACCCGCCTTTCTTGAATGGCTTCGTGTTACTCAGCCGTGCCCTGGCAGGAATGGAACTCCATCAGGGAACAGGGCAGCT 561 CTGTTTGAATGGGGTGAAAAACAGCAAAATTAATTCTTAGCAAGCTCCTTGTTCTCTACTGTTCACCGGGACCTGGCTGG 641 CAAATGACTTAGCTATTAGTATATTTAAAAACTGTTCAAAAGCAAAAGAGAAGGAACAGGAATGAAAGGAAACCTTCCCT 721 TAACTCTTTCTGCTTCCCATAGCAGGTCTGGTTCCTGCTCCCCGCCTAGGACAGGAGCTGTCTGGAGCTCCACCTTTGCA 801 AAGAAAGGAAAAACACAAATTGCCCCCAGATTGGCCCAGTGGCATGCCATTAGGTGATTTTGCATAGGGGCCATATCATT 881 CATGGCCAAAAAAAACCAAAAAGCAAAAAACAAAAACAAGTCCCATGTCCTACTGACTCTAGTTCTTCCAGTCGTTATCC 961 TCTGCTGTCTCTCTGGCATCCTATGAATCAGATCAAGCCCATGCTGTTGTTGGTTTTTAAGGTTTCTTTCAATAATAGGC 1041 TAAGGAAAGACATGTTTTTCTCTTTTAAATCTCTGCAACTCCAAAGTAGACTCCTTCGAACGTATTTAATTTGGCCTTTT 1121 CAGCTTTCTTCTTGCCCAGCTCTGTCGAATTCATGGGTGTGTGTGCACATGTTGGTTTCACTCACCCAGAGTAATTTTGT 1201 GAGCATGCATGTGCTTTTTAATTTCTGCTTGAATGTTTGTCCTGCTGTGTTGCAGCTTCTAAAGACATTGTCACCGAGTG 1281 TGTGTGACTCAAAGATCAAGAGTGAGGCTAAACTGCGACCCCAACATCACTTCCTTCATGGAAAGGTGTTGGCGCTGATG 1361 TAGCTCATGGAAGGATCAGACTGGGAACCACAGAGGAAGGATGAGGTGGGATGTGGAGGTCAGAGCATCTCACGAGAGTC 1441 CCTCAGGCTCTGCAACACTAGATTCGAATATGAGCCTAGGGTTTCCCCAACACGTGCGTGCATATGAAACCACATCATGA 1521 TTCCCGACGTGAGTTAGATGAGGGAGAGTTTGTGTAACTCCACACCCAGGAGGGTAAGCCACTTTATTATCATGCTTTGG 1601 GGCTGTGCTTAAGAATTTAAGCTCTGTTTTAAAGCCGAAGAAGAAAACATTTGAATTTACCTTCATATGCCACTAAGAAC 1681 AAAAGCTCTGAAGTTCTTCCTGCTGGCACCAAATATTAGGATTACAAGCTGTCTCTCTGACACCAGTGGTAAAAAAGCAA 1761 GTAGAATAGTTTCTGAGTCTGTGTTGCAGCCTCTGACACGTGGCTCACCGCTGTCATTTGGGGGATGGAATGAACAGTCA 1841 CTGTTCTATAGCATCCTCCTGTGCTCTTACCTAAGGAATCTAAATTGTCCTAGCCTTCCATTGCTATGCACTGAATGAGG 1921 ACTACTCTCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTGGATCTACTAACATGTTTAG 2001 CAAATGGCTCTGACAGGGTGGCCATGAGCAGATGAGACCAGCTCTTGCTTGGTTGGAAGCCACACTGCAGTTTGCAGTTT 2081 AGCCTTTGGTGTCTCAGTGGCTTCTTGCTTATTCCATGCTTTTTCTATCCCATCCTCTCTCTGTGCCCTCCTGCAATGGC 2161 AGCCTTGGCACAATGCCTGGGTGTCCTCATCCTTGCTTTACTCTGGAAAGTGTGGGGATGGAGAGGATGGTGCATTTCCA 2241 GTGCTTCCTTACCTGTCAATAACAATGGTGGCCACCTGGGTCCCAGCACTTGGCTGGTGGAGAGATTTTTTTCATTATGG 2321 AGCTAATAAAGGGTCCCTACGTTTTACATTGATTAATGAATTATCACCCAGACATGTGCAGATGAAATGTCAATATAAGA 2401 AAAATCAAGGTATTTGGGAAACATGGGCATAATCAGGTAGTTTTGCTAAAATTCCTCTTCCTTGGTCTACATAAAGAAGA 2481 CATGGGTCTGTCATAGAATGGGGACATTAGACTGAAAACTGGGACAACCCCCTTCCTTATTTTATAGAGACTAGGAGTTA 2561 AGGGGCCTGCCTAAGATTGCAGTGATAAAGAACTGAACCCTAAATCAGCTCCCACTAATGAAACCCTGCTTTCCTTGTAT 2641 CTTTTAAACTCAGTTCTGCATCCAACTTGAGAAGAAAAAAAGCTTCTTTCCATATCAAGTACCATATGAGTTCATTTAAA 2721 CTGCACCTTGCAGAAATGCATTGCCAGAAAGCACCAGTAGCCTCCTATCTGCAAGCAGAGTAGTGCTCTGCTCTGGGGAG 2801 GGGTCATTGGAAACCATAATGCAGAGTGGGCCCCCTACTCCATTTCCCAGCAAAAGGCTCCAGCTGGAGGGATGGGTTGT 2881 GGGGCAACCTGGTTCCTGCTAACTGCCAGATTGAATGTGTGGGCTAGAATGCCTGCACATTTAGTTAAACTGGGCTCAGC 2961 ATGCTTGTCCTCAAAATGTCCATCCTGGTCACAGCACACAAGATGGCTATTGGTCTGCTTTTACCCTACCCTGTACTATA 3041 CATGAAAATTCCAGTTATTAACACACTCAAACTGGTGGAGCTTGTTCACCCTAGGAAGGGGATTGTATATATGGCAGGCT 3121 TCCCTGGTGCCGATGTAAAGGGCTACATTTGGGAACATTTGACTTCCTTGGGACTCTTAAGTGCATAATGATGGCATGAA 3201 GTAAAAGGGGCCTCAATGATGATAGGAAAATCAGTTCTTTTAAAATTTCTTCAAGAAAATCCAGGCTATCACATAGTCTT 3281 TCTGTGTGACTTATTAGGAGATAGGAAGAGCATTGGGAAACTTGCACAGCTAGCTATGCATCTACATTTTGGTTTGGGGT 3361 TAGTTATGAAATGTTCTTAATATGACGTGTTCAATAACTTCACATAAACTTCCTGTTCTCCAAAACCTCAAAGAGATAGA 3441 GTTAATGAGTTGTTGTTTTTTTTTAAATGGGGGTAGTTTTCTATCTGTCATGGGCTCTAGCATCTACTCCGCTACCCAAT 3521 TCTGTCATCTCCAAGCTGAGTTTCCTCTTCTGAGGCAGAGGCTGGAGCAGTTCTTTTTCAGTTCTCATCCTCTCCATCCC 3601 AATCCAGTATATCAATCAACTCTAACTCGGAGACGTCTAGCTGGCAATGTTTCTAAAACTTTCACTGGATTTCTTTAGAC 3681 ATTGAAGCAAACATTTTTTTCTAAGAATTGCTTCTCAGATGATGATATCAAATGTATATGCTTTTGCAAGTTTGAAAAGT 3761 TCAAATTAACCACTTTTGACTAGGTAAGTCTTTCTAAAAACCATTTAAAGCTAACTGGGTCTTAGCATCCTCCTGTGTAT 3841 GGAAGAGACAGGTGACCGCTCCAGGTTGGGTGCTCACAGAACCCTTTTCCTGACTCTCATGGAAGATGGTGGAAGGAAAA 3921 TAGACTGTCTCATCAACCCTCCTGTGTCCTCTGAAGCAATCTCAGTTTTTATTAACCACCTCTTCTGTGTTTCTGGTAGC 4001 TATTTAACCTGTATTTAATCTGTACTTCCTATGCCAGCCTCAATTTTATTTGATTTTTACAATTATTCTCTTCTAACCAA 4081 TGAAGTGTTTGTCAGTATGCCCCAAAGCTTGCTCTTTTGTGCTCCCTTTTGAATAACTTTCTATCCAGAAAAAGAGATTA 4161 TTTGGGACTTGAGATTTGCAGTGATACCAACTTATAGCAATGATGTACTTTAAGGGAACTACCCAACTATGTTGTGATAG 4241 AAGAAAGAGAAACCTTCACTTTGGCATTTTTTTTTAATCACTGTTTATTTTTCTGTTTGCGGCCCAGGAAGCAGTGGGAG 4321 GTGGTGGCAGATATGCTTTGCATATGGATTGTTATGTTTTTATTTGGGCAAGTTTAATCATGGAAAACTCAAAAAGAAGG 4401 GGGGAAATGGTCAGTTTAAGCCAAAAGAAACTTTCTAAACAATGTATAGGTACACAGCAAAATTAAACAAATCCAACAAT 4481 TTCTGAAGCTTAGTGTAATTGAGTGGTGGTTGTTATTCAATAAAATTATTCCCAAAAGTGTTTCTCCTAAGAGTGCAGTT 4561 CCCATGAGTCACTTCCTGAACCCATTGACCAAAGGTGGACAGAGACAATCCTGTAGACCTTGACATTCAGAAAGATGTGA 4641 GCTGCTTACTGATCATATATGCATACGTTTCTTTACAGCAGAGGAAACCATTGTCCACAAAACTGATGTTCTTTTGGGGT 4721 TTTATGTACAGACTTGTCCAATCATGTGTGTGGTTCCTGCGAGTTGCTGATGACTCCGCATTGAAGCTCTCTGAGTTCTT 4801 TGATTTTAAGTTGGGTTTATGGAATTTTTTCAAATGTTGGAAGGTGTGTGGTTCTTCCTGCCCTCCCTCCCCTTTTGGAA 4881 ATATGAAAGCAAATGTTTAGAAGAATTCCTTTTGAAAAGCTGTGTCGTGTTCCCTGTGAAACTGAGCAGGTGTGTGTTGG 4961 CGCGCTAAGTGCCACATGCTTGTGTGTAGAGGAGGAGGTGGCCCTGCCGGCTCCGCGCTGCTGTGCCTGTGATCCCTACC 5041 TGCTCCCCGCTCCTGTTGCCAGCAGCACTCACTGCACTCCTTTGTCATATACTCTGCATCACTGTCATACTCACAACTTC 5121 GTGAATAAAGTTGTGTGCTTTATTCGTAGAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | BC-3 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM796039. RNA binding protein: AGO2. Condition:4-Thiouridine
PAR-CLIP data was present in GSM796040. RNA binding protein: AGO2. Condition:4-Thiouridine
... - Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Gottwein E; Corcoran DL; Mukherjee N; et al. - Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | EF3D-AGO2 , LCL-BAC |
Disease | MIMAT0004772 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1020021. RNA binding protein: AGO2. Condition:EBV B95-8-infected
"PAR-CLIP data was present in GSM1020023. RNA binding protein: AGO2. Condition:EBV B95-8-infected
... - Skalsky RL; Corcoran DL; Gottwein E; Frank et al., 2012, PLoS pathogens. |
Article |
- Skalsky RL; Corcoran DL; Gottwein E; Frank et al. - PLoS pathogens, 2012
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus linked to a number of B cell cancers and lymphoproliferative disorders. During latent infection, EBV expresses 25 viral pre-microRNAs (miRNAs) and induces the expression of specific host miRNAs, such as miR-155 and miR-21, which potentially play a role in viral oncogenesis. To date, only a limited number of EBV miRNA targets have been identified; thus, the role of EBV miRNAs in viral pathogenesis and/or lymphomagenesis is not well defined. Here, we used photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) combined with deep sequencing and computational analysis to comprehensively examine the viral and cellular miRNA targetome in EBV strain B95-8-infected lymphoblastoid cell lines (LCLs). We identified 7,827 miRNA-interaction sites in 3,492 cellular 3'UTRs. 531 of these sites contained seed matches to viral miRNAs. 24 PAR-CLIP-identified miRNA:3'UTR interactions were confirmed by reporter assays. Our results reveal that EBV miRNAs predominantly target cellular transcripts during latent infection, thereby manipulating the host environment. Furthermore, targets of EBV miRNAs are involved in multiple cellular processes that are directly relevant to viral infection, including innate immunity, cell survival, and cell proliferation. Finally, we present evidence that myc-regulated host miRNAs from the miR-17/92 cluster can regulate latent viral gene expression. This comprehensive survey of the miRNA targetome in EBV-infected B cells represents a key step towards defining the functions of EBV-encoded miRNAs, and potentially, identifying novel therapeutic targets for EBV-associated malignancies.
LinkOut: [PMID: 22291592]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | LCL-BAC-D2 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1133252. RNA binding protein: AGO2. Condition:Untreated
... - Majoros WH; Lekprasert P; Mukherjee N; et al., 2013, Nature methods. |
Article |
- Majoros WH; Lekprasert P; Mukherjee N; et al. - Nature methods, 2013
High-throughput sequencing has opened numerous possibilities for the identification of regulatory RNA-binding events. Cross-linking and immunoprecipitation of Argonaute proteins can pinpoint a microRNA (miRNA) target site within tens of bases but leaves the identity of the miRNA unresolved. A flexible computational framework, microMUMMIE, integrates sequence with cross-linking features and reliably identifies the miRNA family involved in each binding event. It considerably outperforms sequence-only approaches and quantifies the prevalence of noncanonical binding modes.
LinkOut: [PMID: 23708386]
|
CLIP-seq Support 1 for dataset GSM1020021 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | EF3D-AGO2 / EBV B95-8-infected, 4-thiouridine, RNase T1 |
Location of target site | ENST00000392952.3 | 3UTR | UUGGCGCUGAUGUAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22291592 / GSE41437 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1020023 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | LCL-BAC / EBV B95-8-infected, 4-thiouridine, RNase T1 |
Location of target site | ENST00000392952.3 | 3UTR | UUGGCGCUGAUGUAGCUCA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22291592 / GSE41437 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM1133252 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | LCL-BAC-D2 / Untreated |
Location of target site | ENST00000392952.3 | 3UTR | UUGGCGCUGAUGUAGCUCA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23708386 / GSE46611 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM796039 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-3 / 4-Thiouridine |
Location of target site | ENST00000392952.3 | 3UTR | UUGGCGCUGAUGUAGCUCA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset GSM796040 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-3 / 4-Thiouridine |
Location of target site | ENST00000392952.3 | 3UTR | UUGGCGCUGAUGUAGCUCA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
59 hsa-miR-499a-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT130131 | TXNIP | thioredoxin interacting protein | 2 | 2 | ||||||||
MIRT133678 | ETNK1 | ethanolamine kinase 1 | 2 | 2 | ||||||||
MIRT252103 | NAPG | NSF attachment protein gamma | 2 | 2 | ||||||||
MIRT260160 | IGFBP4 | insulin like growth factor binding protein 4 | 2 | 2 | ||||||||
MIRT388009 | DR1 | down-regulator of transcription 1 | 2 | 2 | ||||||||
MIRT441692 | ABLIM1 | actin binding LIM protein 1 | 2 | 6 | ||||||||
MIRT447799 | EPC2 | enhancer of polycomb homolog 2 | 2 | 2 | ||||||||
MIRT450657 | STYX | serine/threonine/tyrosine interacting protein | 2 | 4 | ||||||||
MIRT456843 | ZNF460 | zinc finger protein 460 | 2 | 2 | ||||||||
MIRT464134 | VPS35 | VPS35, retromer complex component | 2 | 2 | ||||||||
MIRT465101 | TSC22D3 | TSC22 domain family member 3 | 2 | 4 | ||||||||
MIRT470051 | PTGFRN | prostaglandin F2 receptor inhibitor | 2 | 2 | ||||||||
MIRT474146 | LIMA1 | LIM domain and actin binding 1 | 2 | 6 | ||||||||
MIRT474153 | LIFR | LIF receptor alpha | 2 | 2 | ||||||||
MIRT485327 | MYO1D | myosin ID | 2 | 2 | ||||||||
MIRT496403 | ZSCAN16 | zinc finger and SCAN domain containing 16 | 2 | 2 | ||||||||
MIRT497280 | MAF | MAF bZIP transcription factor | 2 | 2 | ||||||||
MIRT500970 | SPTSSA | serine palmitoyltransferase small subunit A | 2 | 2 | ||||||||
MIRT501536 | POM121C | POM121 transmembrane nucleoporin C | 2 | 6 | ||||||||
MIRT505174 | WDR76 | WD repeat domain 76 | 2 | 4 | ||||||||
MIRT505203 | UQCRB | ubiquinol-cytochrome c reductase binding protein | 2 | 4 | ||||||||
MIRT506745 | LIN54 | lin-54 DREAM MuvB core complex component | 2 | 4 | ||||||||
MIRT506799 | KLHL15 | kelch like family member 15 | 2 | 6 | ||||||||
MIRT525718 | DCAF12L2 | DDB1 and CUL4 associated factor 12 like 2 | 2 | 2 | ||||||||
MIRT530014 | SRRM1 | serine and arginine repetitive matrix 1 | 2 | 2 | ||||||||
MIRT531457 | PROSER2 | proline and serine rich 2 | 2 | 2 | ||||||||
MIRT532272 | CD93 | CD93 molecule | 2 | 2 | ||||||||
MIRT538715 | CAPRIN2 | caprin family member 2 | 2 | 4 | ||||||||
MIRT547356 | NAT8L | N-acetyltransferase 8 like | 2 | 2 | ||||||||
MIRT551468 | TRIM59 | tripartite motif containing 59 | 2 | 2 | ||||||||
MIRT555444 | NT5C3A | 5'-nucleotidase, cytosolic IIIA | 2 | 2 | ||||||||
MIRT555674 | PGAM4 | phosphoglycerate mutase family member 4 | 2 | 4 | ||||||||
MIRT557816 | FOXO1 | forkhead box O1 | 2 | 2 | ||||||||
MIRT557853 | FIGN | fidgetin, microtubule severing factor | 2 | 2 | ||||||||
MIRT557880 | FEM1B | fem-1 homolog B | 2 | 4 | ||||||||
MIRT562299 | GLO1 | glyoxalase I | 2 | 2 | ||||||||
MIRT563245 | QRFPR | pyroglutamylated RFamide peptide receptor | 2 | 2 | ||||||||
MIRT565571 | SLC7A2 | solute carrier family 7 member 2 | 2 | 2 | ||||||||
MIRT566214 | PTMA | prothymosin, alpha | 2 | 2 | ||||||||
MIRT575544 | Map4 | microtubule-associated protein 4 | 2 | 2 | ||||||||
MIRT609316 | FXYD6 | FXYD domain containing ion transport regulator 6 | 2 | 2 | ||||||||
MIRT609362 | ACOT2 | acyl-CoA thioesterase 2 | 2 | 2 | ||||||||
MIRT611163 | BTLA | B and T lymphocyte associated | 2 | 4 | ||||||||
MIRT611749 | CACNA1B | calcium voltage-gated channel subunit alpha1 B | 2 | 2 | ||||||||
MIRT615019 | ELK4 | ELK4, ETS transcription factor | 2 | 2 | ||||||||
MIRT623317 | MAPK1 | mitogen-activated protein kinase 1 | 2 | 2 | ||||||||
MIRT624550 | BMPR1A | bone morphogenetic protein receptor type 1A | 2 | 2 | ||||||||
MIRT633934 | DNAH9 | dynein axonemal heavy chain 9 | 2 | 2 | ||||||||
MIRT635691 | BMP10 | bone morphogenetic protein 10 | 2 | 2 | ||||||||
MIRT646438 | DNAH8 | dynein axonemal heavy chain 8 | 2 | 2 | ||||||||
MIRT651940 | UBN1 | ubinuclein 1 | 2 | 2 | ||||||||
MIRT663605 | TBC1D22A | TBC1 domain family member 22A | 2 | 2 | ||||||||
MIRT689759 | PRR13 | proline rich 13 | 2 | 2 | ||||||||
MIRT691916 | SRXN1 | sulfiredoxin 1 | 2 | 2 | ||||||||
MIRT698678 | TEF | TEF, PAR bZIP transcription factor | 2 | 2 | ||||||||
MIRT700924 | PDS5A | PDS5 cohesin associated factor A | 2 | 2 | ||||||||
MIRT707970 | PDE12 | phosphodiesterase 12 | 2 | 2 | ||||||||
MIRT715290 | CSTF1 | cleavage stimulation factor subunit 1 | 2 | 2 | ||||||||
MIRT722414 | RARS2 | arginyl-tRNA synthetase 2, mitochondrial | 2 | 2 |
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|